文献速递间质性肺疾病呼吸道感染

淋巴管肌瘤病中mTORC1过度激活导致II型肺泡上皮细胞ACE2上调:对COVID-19的启示

mTORC1 hyperactivation in lymphangioleiomyomatosis leads to ACE2 upregulation in type II pneumocytes: implications for COVID-19.
PubMed 文献 · Eur Respir J · 2021-02-11

淋巴管肌瘤病(LAM)中SARS-CoV-2进入受体ACE2在肺泡细胞表达增加,与自然杀伤细胞干扰素通路上调及LAM相关成纤维细胞IL6表达增加相关。LAM是女性因TSC基因突变导致mTORC1信号网络在间充质来源LAM细胞中异常过度激活的进展性囊性肺病。LAM中COVID-19风险未知。

要点

  • LAM患者肺泡细胞ACE2表达增加,可能增加SARS-CoV-2易感性。
  • ACE2上调与NK细胞干扰素通路激活及LAM相关成纤维细胞IL6表达增加相关。
  • LAM中COVID-19风险尚不明确,需进一步研究。

核心结论

  • LAM中mTORC1过度激活导致II型肺泡上皮细胞ACE2上调,可能与NK细胞干扰素通路及成纤维细胞IL6表达增加相关。

研究设计与样本

  • 研究设计与样本量原文未报告。

主要发现

  • LAM中肺泡细胞ACE2表达增加,与自然杀伤细胞干扰素通路上调及LAM相关成纤维细胞IL6表达增加相关。

临床怎么用

  • LAM患者可能存在SARS-CoV-2易感性增加,临床需关注COVID-19风险。

局限性

  • LAM中COVID-19风险未知,需进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Increased pneumocyte expression of the SARS-CoV-2 entry receptor ACE2 in lymphangioleiomyomatosis (LAM) is associated with upregulation of interferon pathways in natural killer cells as well as increased IL6 expression in LAM-associated fibroblasts https://bit.ly/34ChSsg Respiratory failure is among the gravest outcomes of coronavirus disease 2019 (COVID-19), and most of the severe cases are associated with significant lung comorbidities [1]. Lymphangioleiomyomatosis (LAM) is a progressive cystic lung disease of women caused by mutations in tuberous sclerosis genes, resulting in aberrant hyperactivation of the mTOR complex 1 (mTORC1) signalling network in LAM cells, which are of mesenchymal origin [2]. The risk of COVID-19 in LAM is unknown.

来源:Eur Respir J,查看原文。版权归原作者所有。

引用

  1. Tang Y, Kwiatkowski DJ, Henske EP, et al. mTORC1 hyperactivation in lymphangioleiomyomatosis leads to ACE2 upregulation in type II pneumocytes: implications for COVID-19. Eur Respir J. 2021. PMID: 33060154. doi:10.1183/13993003.02737-2020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。